NeuroScientific Advances StemSmart™ Stem Cell Therapy via Special Access Program and Phase 2 Trials in Australia and US

StemSmart™ Platform Technology and Mechanism of Action

NeuroScientific Biopharmaceuticals acquired the StemSmart™ platform, originally developed at Royal Perth Hospital in Western Australia. This therapy is a purpose-built mesenchymal stromal cell (MSC) platform tailored for patients suffering from severe inflammation and few treatment options. The technology exploits the multipotent, non-engrafting characteristics of MSCs, which have the capacity for expansion and multi-lineage differentiation.

StemSmart™ is distinguished by a proprietary activation process that enhances therapeutic activity compared to conventional MSC therapies. The activated cells home to inflammation sites and modulate immune responses across innate and adaptive immunity pathways. At the cellular level, the therapy inhibits natural killer cell activation and proliferation, suppresses pro-inflammatory cytokine release from macrophages and dendritic cells, blocks T-cell proliferation, and promotes regulatory T cell generation. This multi-modal immunomodulatory mechanism addresses complex inflammatory pathways where existing biologics have failed. The manufacturing process—from bone marrow aspirate collection through culture expansion, harvesting, and cryopreservation in liquid nitrogen—is conducted under TGA accreditation to ensure safety, quality, and consistency.

Special Access Scheme Outcomes in Fistulising Crohn's Disease

NeuroScientific has progressed StemSmart™ through the TGA's Special Access Scheme, enabling patients with limited treatment options to access experimental therapies. Four patients with fistulising Crohn's disease—a debilitating condition involving abnormal tunneling between the bowel and skin or other organs—have initiated treatment and achieved clinical response. The company defines clinical response as at least 50% fistula closure or discharge reduction, providing early real-world validation in severe Crohn's patients with limited alternatives.

Fistulising Crohn's disease affects about 25% of Crohn's patients and significantly impairs quality of life, remaining difficult to treat with standard therapies. The Special Access Scheme results are notable because they demonstrate therapeutic activity in patients who previously failed biologic therapies—the most advanced treatments available. This real-world data directly informs the design and patient selection criteria for the planned Phase 2 clinical trial, indicating that early signals from the Special Access cohort are shaping the company's regulatory and clinical development strategy.

Supporting Clinical Trial Data for StemSmart™ Efficacy

Prior to the Special Access outcomes, StemSmart™ demonstrated significant clinical activity in earlier studies. In a Phase 2 trial of refractory Crohn's patients, StemSmart™ achieved a 78% clinical response rate, defined as a Crohn's disease activity index (CDAI) reduction of over 100 points. Additionally, 44% of patients reached remission, defined as CDAI below 150 points. Importantly, no treatment-related safety events were reported.

This cohort consisted of refractory Crohn's patients who had failed existing biologics, representing a population with limited options. The combination of robust efficacy (78% response, 44% remission) and a strong safety profile across multiple clinical programs underpins NeuroScientific's confidence in advancing StemSmart™ into formal Phase 2 development. Consistent therapeutic activity across different patient groups suggests the platform's potential across various Crohn's disease phenotypes.

Crohn's Disease Impact and Market Potential

Crohn's disease imposes a significant public health burden in Australia and worldwide. According to company data, over 70,000 Australians are affected, with more than 1,000 new cases annually. The disease predominantly affects individuals aged 15–40 years, impacting working-age populations. The economic burden is substantial, with annual costs exceeding AUD 3.1 billion in Australia, including AUD 361 million in productivity losses.

The disease's progressive nature leads to complications such as strictures, fistulae, perianal issues, surgeries, and colorectal cancer. Altering disease progression and preventing these complications are key treatment goals. Current therapies, including biologics, have limitations in durability and effectiveness, especially for complex forms like fistulising disease. This unmet need creates a significant opportunity for StemSmart™, which has shown activity in patients unresponsive to existing biologics.

Phase 2 Clinical Trial Planning for Refractory Crohn's Disease in the US

NeuroScientific is preparing a Phase 2 clinical trial for refractory Crohn's disease under the US FDA's Investigational New Drug (IND) program. The trial will be conducted in both the US and Australia as a randomized, double-blinded, two-arm study. Patient criteria and enrollment targets are currently being finalized to optimize efficacy demonstration in a regulatory-grade study. Data from this trial will support partnering for Phase 3 development and global commercialization.

The dual-country approach reflects the global drug development landscape and the need to generate data acceptable to major regulatory bodies. Partnering discussions for Phase 3 and commercialization align with typical biopharma strategies, especially in cell therapy where manufacturing scale and infrastructure benefit from established partners. The randomized, double-blinded design ensures scientific rigor essential for regulatory approval of novel cell therapies.

Phase 2 Trial Development for Fistulising Crohn's Disease in Australia

Concurrently, NeuroScientific is preparing a Phase 2 trial focused on fistulising Crohn's disease in Australia via the TGA's Clinical Trial Notification pathway. This open-label, single-arm study is under development with patient criteria and numbers being finalized. Data generated will support a Marketing Authorisation application with the TGA for this indication.

The open-label design contrasts with the randomized blinded US trial, reflecting different regulatory expectations and existing clinical evidence. The four patients treated under the Special Access Scheme provide the most advanced clinical data for this indication, informing regulatory strategy. Prioritizing Australian regulatory approval allows the company to generate localized efficacy and safety data while preparing for the larger refractory Crohn's trial involving US centers. Success in fistulising disease could validate the StemSmart™ platform and strengthen the refractory Crohn's program.

Expanding StemSmart™ Beyond Crohn's Disease

NeuroScientific aims to extend StemSmart™ applications beyond inflammatory bowel disease into other high-inflammation conditions with limited treatment options. Key areas include renal transplantation and lung transplantation or chronic inflammatory lung diseases. In renal transplantation, StemSmart™ may support immune tolerance and reduce transplant-related inflammation, addressing chronic allograft dysfunction and rejection challenges.

In lung transplantation and chronic lung disease, the platform’s immunomodulatory properties could mitigate inflammatory complications. By broadening indications, NeuroScientific seeks to establish StemSmart™ as a versatile platform therapy for multiple immune-mediated diseases, creating multiple value inflection points as clinical and regulatory progress continues. Success in these areas could expand market potential and partnership opportunities.

Manufacturing, Safety, and Regulatory Compliance

StemSmart™ has demonstrated a strong safety profile across multiple clinical studies, with no serious adverse events reported, reinforcing confidence in the platform. Manufactured under TGA accreditation, the process ensures safety, quality, and consistency at every stage.

The standardized manufacturing workflow starts with bone marrow aspirate collection, followed by culture expansion, passaging, harvesting, formulation, and cryopreservation in liquid nitrogen. This scalable process supports commercial production and addresses logistical challenges through cryopreservation. The proprietary activation step is integrated during manufacturing to ensure consistent therapeutic potency. TGA accreditation guarantees compliance with clinical trial and commercial distribution standards in Australia.

Mesenchymal Stromal Cell Biology and Low Immunogenicity Advantages

Mesenchymal stromal cells offer low immunogenicity, minimizing immune rejection and eliminating the need for donor-recipient matching. StemSmart™ MSCs exhibit low HLA Class I expression, no HLA Class II, and lack co-stimulatory molecules, preventing T-cell mediated immune responses and evading recognition by alloreactive T cells and natural killer cells. This enables a single manufacturing batch to serve multiple patients, enhancing manufacturing efficiency and drug availability compared to patient-specific therapies.

The multipotent nature of MSCs, sourced from bone marrow, adipose tissue, placenta, umbilical cord, and other tissues, provides sourcing flexibility. These cells maintain expansion capacity and multi-lineage differentiation potential, enabling therapeutic cell numbers and biological versatility. Decades of research underpin the biological foundation for StemSmart™’s therapeutic applications.

Investment Outlook and Regulatory Path Forward

NeuroScientific’s approach of advancing StemSmart™ through the Special Access Scheme while preparing formal Phase 2 trials reflects a pragmatic development strategy. The Special Access Scheme simultaneously delivers therapy to patients with urgent needs and generates real-world clinical and safety data that inform formal trial design. This reduces uncertainty and provides early efficacy signals supporting investor confidence and partnership potential. The four patients treated under the scheme represent a meaningful cohort demonstrating clinical response and preliminary validation of the platform.

The upcoming Phase 2 trials are critical regulatory and clinical milestones. Success in either the Australian fistulising Crohn's trial or the US refractory Crohn's trial could enable Phase 3 development and commercial partnerships with established biopharma firms. Key investor milestones include trial initiation, patient enrollment, interim efficacy and safety data releases, and regulatory feedback from the TGA and FDA. Additionally, progress in transplantation and chronic lung disease indications offers longer-term value creation. Investors should monitor announcements on Phase 2 trial progress, regulatory updates, and partnership developments as indicators of clinical and commercial advancement.